Genmab — April 2021

[E_L]

Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

[E_L]

Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

[Bulder]

I assume that only the first epco abs will contain data. The second one looks more like a presenting abs.

[E_L]

makes sense

[E_L]

1 Tiso - Tisotumab vedotin versus investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT‑cx12/GOG 3057, trial in progress).

[Bulder]

The new guy from Vejle is primary author on the firste epco-abs. Will be interesting how new dara are.

[E_L]

13x Dara; i would think the 2 most interesting are on Auriga and Cassiopeia 'part 2' ?

[Bulder]

Hope we'll get the full expansion cohorte.

[Bulder]

That should provide us with data enough to judge on the future of epco.

[E_L]

so that's the abstract that will determine how our summer will be

[E_L]

A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors.

[Bulder]

strange that we don't hear anything from the Cepheus study. It had primary completion earlier this month.

[E_L]

do you think it could be important enough for a late breaker?

[Bulder]

could be

[Sukkeralf]

Or EHA - one of them
would be nice

[GeorgeBest]

https://meetinglibrary.asco.org/results/Glofitamab ?filters=JTVCJTdCJTIyZmllbGQlMjIlM0ElMjJZZWFyJTIyJTJDJTIydmFsdWUlMjIlM0ElMjIyMDIxJTIyJTJDJTIycXVlcnlWYWx1ZSUyMiUzQSUyMjIwMjElMjIlMkMlMjJjaGlsZHJlbiUyMiUzQSU1QiU1RCU3RCU1RA%3D%3D&page=1
Glofitamab har 2 abstracts

[GeorgeBest]

https://meetinglibrary.asco.org/results/Mosunetuzumab ?filters=JTVCJTdCJTIyZmllbGQlMjIlM0ElMjJZZWFyJTIyJTJDJTIydmFsdWUlMjIlM0ElMjIyMDIxJTIyJTJDJTIycXVlcnlWYWx1ZSUyMiUzQSUyMjIwMjElMjIlMkMlMjJjaGlsZHJlbiUyMiUzQSU1QiU1RCU3RCU1RA%3D%3D&page=1 Mosunetuzumab 1 abstract

[Doublo]

Tak Concillado for din kommentar jeg først ser nu, du har selvfølgelig ret, jeg tænkte bare om der var noget man særligt kunne være i tvivl om, p.t.
jeg mener der er indregnet risikoen for at voldgiften ikke bliver til GEN fordel, men det glemmer aktionærerne nok i første omgang! jeg har realiseret en del nu, men har været med siden 2015, og tror fuldt og fast på firmaet.

[StockBull]

Tror ikke det er tilfældet at voldgiftsagen er ensbetydende med uoprettelig skade. Har selv eksempelvis arbejdet for Mærsk i ca. 10 år og i den periode kørte de masser af voldgiftsaget mod andre firmaer og den dag idag samarbejder de på bedste vis med de firmaer. Det er business as usual og det der sker efter sådan en voldgiftsag er at begge parter bliver bedre til at granske kontrakter. Det er jo store professionelle internationale firmaer som ikke vinder noget ved at surmule over en lille tvis

[Helge_LarsenPI-redaktør]

God morgen.